DiagnoCure receives approval from the U.S. regulatory authorities and launches its Previstage(TM) GCC Colorectal Cancer Staging Test

    QUEBEC CITY, Aug. 26 /CNW Telbec/ - DiagnoCure Oncology Laboratories,
based in West Chester, PA, a wholly-owned subsidiary of DiagnoCure Inc.,
announced today that it has received the U.S. CLIA certification required for
the Company to launch its new laboratory developed Previstage(TM) GCC
Colorectal Cancer Staging Test. The sales team can now actively promote the
test, and the Company's U.S. clinical laboratory can perform it and report
patient results worldwide.
    "Receiving this regulatory certification is a major accomplishment in
DiagnoCure's growth strategy, which will strengthen our leadership position in
high-value molecular cancer diagnostics. We can now provide clinicians and
patients with a test using a technology that is 100,000 fold more sensitive
than the current method of staging. We can help answer the fundamental
question that every colorectal cancer patient asks after their surgery: Am I
cured or has my cancer spread?", stated John Schafer, President and CEO of
    DiagnoCure Oncology Laboratories will promote and offer the test directly
to clinicians across the United States. Following the summer pre-launch
marketing campaign, several physicians have already expressed interest in the

    About Previstage(TM) GCC

    Every year in North America, 174,000 people are diagnosed with colorectal
cancer, and 142,000 colorectal cancer surgeries are performed. Staging a
patient with colorectal cancer is crucial because it determines the patient's
course of treatment after the surgery. Current standard of care requires that
pathologists microscopically examine a thin slice of tissue from the lymph
nodes harvested during the patient's surgery to see if cancer has spread.
Currently, up to 25 - 30 percent of patients with no pathologically-positive
lymph nodes (stage I and II cancers) later develop recurrent disease,
presumably through occult metastases that have escaped detection. Most of
these patients do not receive additional therapies such as chemotherapy.
Previstage(TM) GCC provides clinicians with significantly more accurate
information for staging a patient with colorectal cancer that will increase
their confidence in making critical treatment decisions.
    Strong data supports the potential for the GCC test to improve the
current staging of colorectal patients. The National Cancer Institute
sponsored a five-year prospective clinical trial of GCC testing in colorectal
cancer patients. This study has been recently completed and the Company's
collaborators at Thomas Jefferson University are presenting the results at
major medical conferences throughout the year.
    The Previstage(TM) GCC Colorectal Cancer Staging Test is a
laboratory-developed test and its performance characteristics have been
validated and determined by DiagnoCure Oncology Laboratories.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc.,
recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the
first GCC-based molecular test for the management of colorectal cancer. The
Company also has a strategic alliance with Gen-Probe (NASDAQ:   GPRO) for the
development and commercialization of a second-generation prostate cancer test
using PCA3, DiagnoCure's proprietary molecular marker. This test is also
available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in
vitro assay, and in Canada. In addition to its own research, the Company
intends to acquire or in-license additional promising cancer biomarkers from
both academic and commercial institutions. For more information, visit

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF

For further information:

For further information: Investors: J.F. Bureau, CFA, Sr. Vice President
and CFO, DiagnoCure Inc., (418) 527-6100, communications@diagnocure.com;
Media: U.S.: Troy Pearson, Mentus Life Science, (858) 455-5500 X320,
Troy@mentus.com; Canada: Jean-Pierre Trudel, Jean-Pierre Trudel & Associates,
(514) 347-6111, jp.trudel@videotron.ca; Clinicians: DiagnoCure Oncology
Laboratories, Customer Care, 1-877-701-9007, customercare@diagnocure.com

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890